Inquiry Basket

Eftrenonacog alfa, Recombinant Factor IX

Cat# : THP-0066

Product Datasheets COA :

Catalog#	Product Name	Availability	Size	Price	Qty
THP-0066	Eftrenonacog alfa, Recombinant Factor IX	April 25, 2024	1 vial	$3,998.00
Add to Cart Online Order Request a Bulk Order

Related Products

Cat#:	THP-0066
Product Name:	Eftrenonacog alfa, Recombinant Factor IX
Description:	The product is comprised of a single molecule of human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1 via recombinant DNA technology in a human embryonic kidney cell line (HEK293H).
Sequences:	Not Available
Species:	Human
Molecular Weight:	98000.0 Da (Approximate)
Source:	HEK293 Cells
Purity:	>99% by SDS-Page and HPLC analysis
Cas No:	1270012-74-2
Formula:	Not Available
Endotoxin Level:	<0.001 EU per 1 μg of the protein by the LAL method
Biological Activity:	3000U/5ml

Catalog#	Product Name	Size	Price	Inquiry
THP-1108	Recombinant stabilized RSV B prefusion F antigen			Inquiry
THP-1102	Cipaglucosidase alfa; Recombinant Human acid alpha-glucosidase			Inquiry
THP-1101	Pegunigalsidase alfa; Recombinant Human α-galactosidase-A			Inquiry
THP-1104	Efanesoctocog alfa; Recombinant DNA-derived, Factor VIII; F8			Inquiry
THP-1100	Velmanase alfa;Recombinant Human Lysosomal alpha-mannosidase			Inquiry
THP-0067	Recombinant Human Erythropoietin	1 vial	$3,998.00	Add to Cart Order
THP-0052	Recombinant Human F8/Antihemophilic factor	100IU	$698.00	Add to Cart Order
THP-0071	Filgrastim, Recombinant human GCSF	1 vial	$3,998.00	Add to Cart Order
THP-9328	Recombinant Human Hyaluronidase PH20, Fc-tagged	1KU	$398	Add to Cart Order
VAC-0413	Recombinant Hepatitis E Vaccine (E. coli)			Inquiry

For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

CONTACT US

For more information on how our products could help advance your project, please contact us.

Contact Us

ENTER YOUR EMAIL HERE TO SUBSCRIBE.

Pharmaceutical Application:	Eftrenonacog alfa
Applications:	Indicated for the treatment and prophylaxis of bleeding in patients of all age with haemophilia B (congenital factor IX deficiency).
Examples of Clinical Use:	Haemophilia B (congenital factor IX deficiency)
Pharmacodynamics:	In two multinational, phase III studies in previously treated children, adolescents and adults with severe haemophilia B, the product prophylaxis resulted in low median annualized bleeding rates (ABRs), and was associated with reductions in median weekly factor consumption and dosing frequency compared with pre-study FIX regimens. The extension of those studies demonstrated effectiveness in the treatment of bleeding episodes and when used in the perioperative setting in all age groups. In animal models, a single intravenous dose of the product displayed half values approximately three- to four-fold longer than those seen with recombinant FIX.
Mechanism of action:	The coagulation protein factor IX (FIX) is a vitamin K-dependent coagulation factor and one of the critical serine proteases involved in the coagulation cascade. Upon activation by factor XIa in the intrinsic coagulation pathway and by the factor VII/tissue factor complex in the extrinsic pathway, factor IX, in combination with factor VIII, activates factor X. Activated factor X mediates the conversion of prothrombin to thrombin which sequentially leads to thrombin converting fibrinogen into fibrin. A blood clot is then formed. With a mutation in the gene encoding the coagulation protein factor IX (FIX), patients with hemophilia B have factor IX deficiency and are at high risk for recurrent bleeding episodes.
Affected organisms:	Not Available

Eftrenonacog alfa, Recombinant Factor IX

Specification

Pharmaceutical Information

Related Products

Online Inquiry